Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing ...

Emma Heming Willis took to her Instagram Stories on August 10 to share a fun fact about her husband, Bruce Willis. "You ever hear about those kinda guys who don't want their ladies wearing heels so ...

HealthDay News — The mean time to diagnosis (TTD) for dementia is 3.5 years across all types of dementia, according to a review published online July 27 in the International Journal of Geriatric ...

When the actor Bruce Willis was diagnosed with aphasia it drew attention to a common yet widely misunderstood condition. For ...

Researchers at Boston University Chobanian & Avedisian School of Medicine have built an artificial intelligence tool that can ...

Targeting cellular structures called nuclear speckles could be a completely new approach for treating proteinopathies, including Alzheimer's, Parkinson's and prion diseases.

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Targeting cellular structures called nuclear speckles could be a completely new approach for treating proteinopathies—diseases driven by abnormal accumulation of misfolded proteins—such as Alzheimer's ...

A groundbreaking study reveals that reshaping nuclear speckles — tiny structures inside cell nuclei that regulate protein maintenance — could be a novel way to treat proteinopathies like Alzheimer’s, ...